Our newest survey reveals that healthcare professionals (HCPs) value services but don't have strong awareness of them and aren't frequently recommending them to patients.
Accenture has been researching the use, value and awareness of patient services in the top global pharma markets since 2013. Patients have consistently said they want, value and expect patient services from pharma companies—particularly before they are treated for a disease.
of pharma companies are increasing their investments in patient services
(Accenture Research, 2016)
of patients are aware of services available to them
(Accenture Research, 2015)
of patients believe that pharma companies should provide services that complement their products
(Accenture Research, 2014)
Healthcare professionals seldom hear about patient services from pharma companies. When they do hear about them, it is mostly as an add-on to the product, not as an essential element in helping them deliver a better patient outcome.
OF HCPs ARE VERY AWARE OF PATIENT SERVICES
SALES REPS ARE THE PRIMARY WAY HCPs HEAR ABOUT PATIENT SERVICES, BUT ALMOST HALF OF SALES REPS ARE TALKING TO HCPs <25% OF THE TIME ABOUT SERVICES AVAILABLE
OF HCPs ALWAYS PERSONALLY SHARE INFORMATION ON PATIENT SERVICES
…BUT PHARMA COMPANIES AREN'T PRESENTING THEM THAT WAY
PRESENT PATIENT SERVICES AS AN INTEGRATED SOLUTION THAT IMPROVES OUTCOMES
View our country specific decks to see how the key findings differ by location.
HCPs who always share information about services with their patients have a distinct profile worth noting.
Pharmaceutical companies can turn many more HCPs into champions of patient services and in doing so, enable patients to become beneficiaries of those services. To do so, pharma companies should address gaps in these three areas:
Rigorously generate evidence on the effect of patient services on outcomes—starting with clinical trials.
This calls for embedding services into the development process to generate the required data to prove impact on patient outcomes—starting with clinical trials. Capturing this evidence at the very earliest stages of clinical trials will also help prove the value internally to sales reps, medical affairs and budget holders, who will then advocate or allocate resources so that service programs can be developed more effectively and marketed more purposefully.
Refocus commercial functions from developing and marketing brands to designing and marketing holistic patient solutions.
Some organizations have tasked their brand teams with marketing patient services; doing so has typically led to patient services being an afterthought to the product. Other pharma companies have built separate patient services organizations working separately/in parallel to brand or marketing teams; this approach also relegates services to an add-on position. Leading organizations will embed patient services talent into their existing brand teams to enable their organizations to build and market holistic solutions.
Focus “conversations” with HCPs (and the market) on outcomes—across all channels and with greater frequency.
The entire healthcare industry is shifting to a value-based approach, but pharma companies are still talking primarily about their products. Pharmaceutical companies need to embrace an outcomes-first mindset, which means they are bringing an outcome to market, rather than a product. They need to ensure that every communication through every channel leads with outcome—this approach should apply whether they are communicating to the market through the marketing organization, through sales reps, or through
To help your company turn HCPs into Super Recommenders and patients into consistent users of services, visit our Intelligent Patient Services page.
We surveyed 362 healthcare professionals (specialty physicians, primary care physicians and nurse practioners) across the US and Europe to understand their awareness, use, and value of patient services. This is the fourth survey we have conducted on patient services to understand market and growth dynamics and the impact of patient services on patient and economic outcomes. Previous research includes two patient surveys and a pharmaceutical patient services executive survey.
Brain
General
Practitioners
Heart
Lungs
Immune
System
Cancer
Key Findings from a Survey of 200+ Patient Services Executives in the Pharmaceutical Industry.
Learn MoreKey findings and insights from a survey of 10,000 patients around the world examining their unmet service needs in seven different therapeutic areas across the entire patient journey.
Learn MoreAccenture surveyed 2,000 US patients and found they value and expect patient services from pharma companies but are not always receiving them.
Learn MoreFollow our LinkedIn Showcase Page for our latest industry research, trends and insights.
Join the ConversationAccenture’s life sciences experts share their insights and opinions on the pharmaceutical, biotechnology, medical technology and consumer health industries.
Read the Blog